Is the severity of alopecia areata associated with arterial stiffness?

• 出版年: Journal of Research in Medical Sciences
• 主要な著者: Mohammad Taghi Najafi, Robabeh Abedini, Narges Ghandi, Shadab Seraji, Yasaman Sadeghi
• フォーマット: 論文
• 言語: 英語
• 出版事項: Wolters Kluwer Medknow Publications 2023-01-01
• 主題: alopecia areata; arterial stiffness; bioimpedance factors
• オンライン･アクセス: http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2023;volume=28;issue=1;spage=80;epage=80;aulast=Najafi

Background: This study aimed to evaluate the severity of alopecia areata (AA) associations with metabolic syndrome, body composition evaluated by bioimpedance techniques, and arterial stiffness based on pulse-wave velocity analysis. Materials and Methods: This cross-sectional study was conducted on patients referred to AA Clinic at Razi Hospital in 2021 and 2022. Patients with AA with the Severity of Alopecia Tool (SALT) score above 20% and receiving no systemic therapy were included. Patient demographic and clinical information, symptoms of metabolic syndrome, and bioimpedance factors were collected, and the relationship between disease severity, metabolic syndrome, and bioimpedance indicators was evaluated. Results: In this study, 59 patients were examined, with 26 (44.07%) being female and 33 (55.93%) being male. The mean age of the patients was 37.42 years (standard deviation [SD] =11.28). The severity of the disease was assessed using the SALT score, with the mean severity in terms of the percentage being 69.83% (SD = 28.57%). In the regression model, SALT score was independently related to the severity of vascular stiffness after adjusting for the effect of other variables (beta = 0.033, 95% CI = 0.009–0.057, P = 0.046). Moreover, SALT score was significantly related to metabolic syndrome after adjusting for the effect of other variables (OR = 1.035, 95% CI = 1.012–1.059, P = 0.002). Conclusion: This study found that AA severity is associated with a higher chance of having metabolic syndrome and arterial stiffness which may lead to cardiovascular diseases in patients with AA, and screening patients regarding cardiometabolic diseases is mandated.